Japan Tobacco Inc.   Report issue

Contributed to NME For profit Phase 2
Founded: Tokyo Japan (1985)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2000
NCT00686010
First Marketed Drug
2005
elvitegravir (vitekta)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Japan Tobacco Inc.

Active Ingredients

Marketed Drugs (1)

elvitegravir (vitekta) (2005)

Drugs in Phase 2 Trials (1)

ro4402257 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Hyperlipoproteinemia Type II (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1